Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools Obesity

Obesity

Programs, trials, and reported weight change for obesity and overweight.

Data as of 11.07.2026

All studies

Tirzepatide

A Study of Tirzepatide (LY3298176) Plus Mibavademab Compared With Tirzepatide Alone in Adult Participants With Obesity

Eli Lilly · Phase 2 · Completed · Enrollment 392

NCT06373146

Participants reaching a weight loss threshold

Participants reaching threshold, %

Source: Cited trial source. The denominator is the source figure, when it states one.

No selected arm reports a responder percent.

Show as table
Arm≥5%≥10%≥15%≥20%
Tirzepatide (TZP) + Mibavademab (MIBA) [Group A]n/rn/rn/rn/r
TZP + Mibavademab-placebo (MIBA-PBO) [Group B]n/rn/rn/rn/r
TZP + MIBA then Tirzepatide-placebo (TZP-PBO) + MIBA [Group C]n/rn/rn/rn/r
TZP + MIBA [Group D]n/rn/rn/rn/r
TZP + MIBA-PBO [Group E]n/rn/rn/rn/r
TZP + MIBA-PBO then TZP-PBO + MIBA [Group F]n/rn/rn/rn/r
TZP + MIBA-PBO then TZP + MIBA [Group G]n/rn/rn/rn/r
TZP + MIBA-PBO then TZP-PBO + MIBA-PBO [Group H]n/rn/rn/rn/r

Not shown

  • Tirzepatide (TZP) + Mibavademab (MIBA) [Group A]: endpoint not reported
  • TZP + Mibavademab-placebo (MIBA-PBO) [Group B]: endpoint not reported
  • TZP + MIBA then Tirzepatide-placebo (TZP-PBO) + MIBA [Group C]: endpoint not reported
  • TZP + MIBA [Group D]: endpoint not reported
  • TZP + MIBA-PBO [Group E]: endpoint not reported
  • TZP + MIBA-PBO then TZP-PBO + MIBA [Group F]: endpoint not reported
  • TZP + MIBA-PBO then TZP + MIBA [Group G]: endpoint not reported
  • TZP + MIBA-PBO then TZP-PBO + MIBA-PBO [Group H]: endpoint not reported